Serum Cystatin C, a Sensitive Marker of Renal Function and Cardiovascular Disease, Decreases After Smoking Cessation

Masafumi Funamoto; Kana Shimizu; Yoichi Sunagawa, PhD; Yasufumi Katanasaka, PhD; Yusuke Miyazaki; Maki Komiyama, MD, PhD; Hajime Yamakage; Noriko Satoh-Asahara, MD, PhD; Yuko Takahashi, MD, PhD; Hiromichi Wada, MD, PhD; Koji Hasegawa, MD, PhD; Tatsuya Morimoto, MD, PhD

Background: Smoking exerts detrimental effects during the progression of atherosclerotic vascular disease. Serum cystatin C is useful in the evaluation of early renal dysfunction and serves as a cardiovascular prognostic marker. This study measured changes in serum cystatin C after smoking cessation (SC).

Methods and Results: In this study, patients who visited the SC clinic for the first time and succeeded in SC for 1 year were enrolled. In the entire cohort of 86 patients, body mass index (BMI, P<0.001) and waist circumference (WC, P<0.001) increased significantly at 3 months after SC compared with baseline. These values were further increased significantly (BMI, P<0.001; WC, P<0.001) from 3 months to 1 year after SC. Serum cystatin C decreased significantly at 3 months (P=0.045) after SC, and remained unchanged (P=0.482) from 3 months to 1 year after SC. Percent change from baseline to 3 months after SC in serum cystatin C was correlated with the percent change in serum monocyte chemoattractant protein 1 (P=0.047).

Conclusions: Serum cystatin C, a marker of chronic kidney disease, was significantly reduced at 3 months after SC.

Key Words: Cardiovascular disease; Cystatin C; Monocyte chemoattractant protein 1; Smoking cessation
Methods

Cohort Description
The present subjects consisted of the cohort of patients who visited the SC clinic at Kyoto Medical Center, and who had successfully stopped smoking by the 3-month visit to the SC clinic, and who had continued successful SC at 1 year.

Patients and Public Involvement
The present subjects were the same as in past studies. From June 2007 to January 2014, a total of 783 outpatients attended the SC clinic at the Kyoto Medical Center. Of these, 408 patients had successfully stopped smoking after 3 months. Of these who had stopped smoking for 3 months, 101 patients visited the SC clinic at 1 year after the first visit and 3 of them had restarted smoking at this time. Informed consent was obtained from all patients, and none of the patients was coerced into taking part in this study. Attempt to quit smoking was confirmed on expired CO concentration <7 p.p.m. and by the patient’s affirmation of no smoking. The attempt to quit smoking was determined as unsuccessful when the patient stopped visiting during the treatment period or continued visiting but failed to quit smoking.

BMI was calculated as weight in kilograms divided by the square of the height in meters. WC was measured at a point midway between the lowest rib and iliac crest by the study staff at each visit. SBP and DBP were measured in a sitting position after resting >5 min, using an automatic electronic sphygmomanometer (BP-103iII; Nippon Colin, Komaki, Japan). A regular-sized cuff appropriate for Japanese subjects (arm length, 17–32 cm) was used as recommended. At each visit, expired CO concentration was measured with an EC50 Micro Smokerlyzer® (Bedfont Scientific, Kent, UK), which measures end-tidal CO electrochemically with a reported precision of <2%. On initial consultation, nicotine dependence was assessed with the Fagerström test for nicotine dependence (FTND), a globally accepted standard test to assess physical dependence to nicotine25. FTND scores range from 0 to 10, with higher scores indicating more severe nicotine dependence. Number of cigarettes smoked per day was determined by asking the patient the following question: “On average, in the past month, how many cigarettes did you smoke per day?”

Blood Sampling
Blood tests were conducted at first consultation as a screening and at 3 months and 1 year after the first visit to assess changes in biochemistry and hematology profiles. Blood samples were collected from the antecubital vein 2–3 h after lunch. Blood samples were immediately centrifuged at 3,000 rpm for 10 min at 4°C. Serum MCP-1 was quantified on sandwich enzyme immunoassay for human MCP-1 (QuantikineE; R&D Systems, Germany) according to the manufacturer's protocol. Serum cystatin C was treated with transdermal nicotine patches or oral varenicline. On subsequent visits, maintenance of SC was evaluated, and a nurse and a doctor gave specific advice related to the continuation of SC. At the end of the 3-month anti-smoking treatment, SC status was re-evaluated. Abstinence was confirmed on expired CO concentration <7 p.p.m. and by the patient’s affirmation of no smoking. Attempt to quit smoking was determined as unsuccessful when the patient stopped visiting during the treatment period or continued visiting but failed to quit smoking.

SC Clinic and Data Collection
Anti-smoking treatment was conducted according to the Standard Procedures for Anti-Smoking Treatment (originally issued in March 2006 by the Japanese Circulation Society, Japan Lung Cancer Society, and Japanese Cancer Association). Patients were examined on their first visit and at 2, 4, 8, and 12 weeks thereafter. All patients were examined on their first visit and 3 of them had restarted smoking at this time. Serum data were anonymized with no personal identifiers. This study is part of the clinical trial entitled “Study of the Effect of Smoking Cessation on Cardiovascular Risk”. The ethics review board of the National Hospital Organization at Kyoto Medical Center approved the study protocol.

Table 1. Changes in Clinical Parameters From Baseline After Smoking Cessation

| Parameter | n | Baseline | 3 months | 1 year | p-value | Baseline vs. 3 months | Baseline vs. 1 year | 3 months vs. 1 year |
|-----------|---|----------|----------|--------|---------|----------------------|---------------------|-------------------|
| BMI (kg/m²) | 78 | 23.1 (21.5–25.3) | 23.9 (22.0–26.0) | 24.4 (22.2–26.7) | <0.001* | <0.001* | 0.001* |
| WC (cm) | 76 | 86.6±9.9 | 88.2±9.9 | 89.4±9.5 | <0.001* | <0.001* | 0.021* |
| SBP (mmHg) | 80 | 131±16 | 126±17 | 127±18 | 0.011* | 0.070 | 0.609 |
| DBP (mmHg) | 80 | 76±11 | 75±10 | 75±11 | 0.555 | 0.801 | 0.857 |
| HbA1c (mg/dL) | 67 | 5.8 (5.6–6.1) | 5.8 (5.5–6.3) | 5.8 (5.6–6.2) | 0.209 | 0.364 | 0.709 |
| LDL-C (mg/dL) | 67 | 115.7±30.1 | 120.7±32.7 | 115.0±30.5 | 0.289 | >0.999 | 0.119 |
| HDL-C (mg/dL) | 75 | 53.0 (45.0–63.0) | 55.0 (45.0–72.0) | 57.0 (45.0–68.0) | 0.002* | 0.073 | 0.042* |
| TG (mg/dL) | 77 | 137 (99–201) | 149 (112–210) | 150 (119–213) | 0.011* | 0.088 | 0.807 |
| Cystatin C (mg/L) | 86 | 0.77 (0.7–0.9) | 0.76 (0.6–0.9) | 0.75 (0.6–0.9) | 0.045* | 0.135 | 0.482 |
| MCP-1 (pg/mL) | 86 | 409 (339–475) | 422 (346–484) | 404 (352–449) | 0.380 | 0.706 | 0.218 |
| hsCRP (mg/dL) | 86 | 0.75 (0.3–2.5) | 0.70 (0.3–2.7) | 0.66 (0.3–1.8) | 0.703 | 0.241 | 0.077 |
| CO (p.p.m.) | 84 | 12.0 (7.0–19.5) | 1.0 (1.0–2.0) | 2.0 (1.0–2.0) | <0.001* | <0.001* | 0.423 |

Data given as n, mean±SD or median (IQR). *P<0.05. BMI, body mass index; CO, carbon monoxide; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MCP-1, monocyte chemotactic protein-1; SBP, systolic blood pressure; TG, triglyceride; WC, waist circumference.
measured on a latex immunoturbidimetric assay using an automated analyzer (JCA-BM8060; JEOL, Japan). All assays were performed by an investigator blinded to the sample sources.

**Statistical Analysis**

All statistical analyses were performed by a professional statistician using SPSS version 17.0 (SPSS, Chicago, IL, USA). Normality was assessed using the Shapiro-Wilk test. Clinical data before treatment were compared with those 3 months and 1 year after SC therapy using paired t-test for parametric data and Wilcoxon signed-rank test for non-parametric data (Table 1). Linear regression analysis was performed to identify factors related to the percent change in serum cystatin C (Table 2. Supplementary Table).

### Results

In the study cohort of 86 patients, none of the patients received dialysis. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, 7 patients; Ca²⁺-blocker, 9 patients; diuretics, 6 patients; α-blocker, 1 patient; β-blocker, 2 patients; anti-diabetic drug, 4 patients; nitrates, 2 patients. Table 1 lists clinical data at baseline, 3 months and 1 year after SC. Briefly, there were 56 men and 30 women, with a mean age of 61±13 years. Patients smoked 23±11 cigarettes per day for 39±11 years. Mean FTND score of the final cohort was 6.5±2.3. The concentration of expired CO decreased significantly at 3 months (P<0.001) and at 1 year (P<0.001) after SC compared with baseline. BMI (P<0.001), WC (P<0.001), high-density lipoprotein cholesterol (HDL-C; P=0.002) and TG (P=0.011) increased and SBP (P=0.011) decreased significantly at 3 months after SC compared with baseline. At 1 year after SC, BMI (P<0.001), WC (P<0.001) and HDL-C (P=0.042) were further increased significantly compared with those at 3 months after SC. Serum cystatin C at baseline ranged between 0.41 and 1.53 mg/dL, and it decreased significantly (P<0.045) at 3 months after SC, but it remained unchanged (P=0.482) from 3 months to 1 year after SC (Table 1).

Next, linear regression analysis for the entire cohort of 86 patients was performed to assess correlations between percent change in serum cystatin C from baseline to 3 months after SC and percent changes in clinical parameters during the same time interval, with adjustment for sex (Table 2). Consequently, there was a significant correlation between percent change in serum cystatin C and percent change in serum MCP-1 (P=0.05). Additionally, a significant inverse correlation between percent change in serum cystatin C and percent change in WC (P=0.05) was noted. These findings were similar to the results of the linear regression analysis conducted without adjustment for sex (Supplementary Table).

### Discussion

Serum cystatin C is a sensitive marker of early renal function and serves as a prognostic marker of cardiovascular disease. In the present study, serum cystatin C decreased significantly soon after SC. Cystatin C is shown to strongly correlate with the elasticity of blood vessel walls in type 2 diabetic patients and may be a useful marker for asymptomatic early arteriosclerosis. SC is also associated with improved vascular endothelial function and increased cerebral blood flow. Taken together, the significant decrease in serum cystatin C may indicate SC-induced improvement of vascular function and increase in blood flow. Renal function naturally decreases with age. Serum cystatin C has been reported to increase by 0.55 mg/L in a span of 25–30 years, that is, from <65 years of age to >80 years old, suggesting that serum cystatin C increases by 0.02 mg/L per year as part of the natural course. In the present study, however, median serum cystatin C was unchanged or decreased from that of baseline to 1 year after the start of SC therapy, suggesting that SC suppresses a natural tendency to increase in serum cystatin C.

It is well known that body weight increases after SC. In this study, body weight increased from baseline to 3 months after the start of SC therapy. Serum cystatin C, however, significantly decreased during this same time period. In addition, from 3 months after the start of SC therapy to 1 year after the start of SC therapy, body weight further increased while serum cystatin C was unchanged or slightly decreased. These data suggest that the adverse effects of gaining weight have been canceled by the beneficial effects of SC.

Serum MCP-1 is highly chemotactic for monocytes and macrophages; it induces macrophage infiltration of vascular lesions and subsequent formation of foam cells. In addition, induction of various cytokines by MCP-1 contributes to the exacerbation of atherosclerosis through plaque formation. Serum MCP-1 plays a key role in atherosclerosis progression as well. In the present study the percent change in serum MCP-1 was significantly correlated with the percent change in serum cystatin C during the 3 months after SC. This raises the possibility that serum cystatin C might also be associated with the atherosclerotic process. Serum cystatin C has been shown to be a predictor of cardiovascular disease. Whether serum MCP-1 and cystatin C are directly related remains unclear. The change in serum level of both factors in the current study might reflect a reduction in vascular inflammation following SC. Association of both serum MCP-1 and cystatin C with cardiovascular disease with an arteriosclerosis component indicates that a decrease in serum cystatin C following SC might reflect a reduced risk of cardiovascular events.

| Table 2. Indicators of Percent Change in Serum Cystatin C After SC† |
|--------------------------|-----------|-----------|
| Sex-adjusted | β         | P-value   |
| % change BMI          | 0.436     | −0.176    | 0.131     |
| % change WC           | 0.431     | −0.235    | 0.036*    |
| % change SBP          | 0.136     | −0.141    | 0.214     |
| % change DBP          | 0.129     | −0.153    | 0.166     |
| % change HbA1c        | 0.161     | −0.083    | 0.454     |
| % change HDL-C        | 0.066     | 0.033     | 0.774     |
| % change HDL-C        | 0.079     | 0.021     | 0.848     |
| % change TG           | 0.021     | −0.029    | 0.795     |
| % change MCP-1        | 0.084     | 0.216     | 0.047*    |
| % change hsCRP        | 0.001     | −0.194    | 0.078     |
| % change CO           | 0.082     | 0.071     | 0.532     |

†Sex-adjusted linear regression analysis. *P<0.05, β, standardized regression coefficient. Other abbreviations as in Table 1.
Body weight increase leads to increases in muscle mass and serum creatinine. Actual renal function, however, may have improved after SC because cystatin C decreased in the present study. Cystatin C has been reported to be associated with inflammation markers such as CRP, and in the present study the percent change of serum cystatin C from baseline to 3 months after the start of SC therapy was positively correlated with that of the inflammation marker MCP-1. Therefore, it is possible that suppression of vascular inflammation by SC decreases serum cystatin C.

This study for the first time has determined that serum cystatin C, a sensitive marker of renal dysfunction, was decreased significantly at 3 months after SC. An association of the decrease in serum cystatin C after SC with a similar change in serum MCP-1, may reflect alleviation of vascular inflammation. Therefore, significant decrease in cystatin C at 3 months after SC might indicate a decrease of cardiovascular risk.

Study Limitations

The sample size of this study was small, and the follow-up period was 1 year. A large-scale, long-term study is needed to validate the present findings. Also, the endpoint of this study was the measurement of a biomarker of renal function and cardiovascular disease. A large-scale, long-term follow-up study with cardiovascular or renal events as the primary endpoint will clarify the clinical significance of the present data.

Acknowledgments

The authors wish to sincerely thank and acknowledge the individuals who helped to facilitate this study. The authors also thank Ms. Yuko Iida for her work as clinical research coordinator.

Disclosures

The authors declare no conflicts of interest.

References

1. Fagerstrom K. The epidemiology of smoking: Health consequences and benefits of cessation. Drugs 2002; 62: Suppl 2; 1–9.
2. Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther 2013; 93: 526–538.
3. Croca S, Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2017; 31: 364–372.
4. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al; Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519–526.
5. Halimi JM, Giraudieu B, Vol S, Caces E, Nivet H, Lebranchu Y, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285–1292.
6. Ishizaka N, Ishizaka Y, Toda E, Shimomura H, Koike K, Seki MM, et al. Vascular functional and morphological alterations in smokers during varenicline therapy. Osaka City Med J 2015; 62: 75–78.
7. Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol 2010; 14: 584–588.
8. Wei Z, Xuelian G, Chao L, Jing L. Correlation between the levels of serum cystatin C and substance P in peripheral blood in diabetes mellitus patients complicated with hypertension. Exp Ther Med 2018; 16: 1159–1164.
9. Muslimovic A, Tulumovic D, Hasanspahi S, Hamzic-Mehmedbasic A, Temunovi R. Serum cystatin C. Marker of inflammation and cardiovascular morbidity in chronic kidney disease stages 1–4. Mater Sociomed 2015; 27: 75–78.
10. Hald J, Overgaard J, Grau C. Evaluation of objective measures of smoking status: A prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol 2003; 42: 154–159.
11. Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J 1990; 69: 763–765.
12. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 119–127.
13. Rustin TA. Assessing nicotine dependence. Am Fam Physician 2000; 62: 579–584, 591–592.
14. Yamashita H, Nishino T, Obata Y, Nakazato M, Inoue K, Furu苏 A, et al. Association between cystatin C and arteriosclerosis in the absence of chronic kidney disease. J Atheroscler Thromb 2013; 20: 548–556.
15. Kaneko R, Sawada S, Tokita A, Honkura R, Tamura N, Kodama S, et al. Serum cystatin C level is associated with carotid intima-media thickness in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2013; 1833–1839.
16. Suzuki Y, Matsushita K, Seimiya M, Yoshida T, Sawabe Y, Ogawa M, et al. Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes. Clin Chim Acta 2012; 413: 1853–1859.
al. Does smoking cessation with varenicline worsen vascular endothelial function? *BMJ Open* 2013; 3: e003052.

32. Rogers RL, Meyer JS, Judd BW, Mortel KF. Abstention from cigarette smoking improves cerebral perfusion among elderly chronic smokers. *JAMA* 1985; 253: 2970 – 2974.

33. Tanaka A, Suemaru K, Araki H. A new approach for evaluating renal function and its practical application. *J Pharmacol Sci* 2007; 105: 1 – 5.

34. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. *N Engl J Med* 2018; 379: 623 – 632.

35. Takahashi M, Masuyama J, Ikeda U, Kasahara T, Kitagawa S, Takahashi Y, et al. Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. *Circ Res* 1995; 76: 750 – 757.

36. Seino Y, Ikeda U, Takahashi M, Hojo Y, Irokawa M, Kasahara T, et al. Expression of monocyte chemoattractant protein-1 in vascular tissue. *Cytokine* 1995; 7: 575 – 579.

37. Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. *Curr Pharm Des* 2014; 20: 4580 – 4588.

38. Angelidis C, Deftereos S, Giannopoulos G, Anatoliotakis N, Bouras G, Hatzis G, et al. Cystatin C: An emerging biomarker in cardiovascular disease. *Curr Top Med Chem* 2013; 13: 164 – 179.

39. Shin MJ, Song SH, Kwak IS, Lee SB, Lee DW, Seong EY, et al. Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis. *Clin Exp Nephrol* 2012; 16: 456 – 463.

40. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. *Ann Biol Clin (Paris)* 2010; 68: 517 – 529.

41. Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? *J Cardiovasc Med* 2013; 62: 331 – 335.

42. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. *Kidney Int* 2004; 65: 1416 – 1421.

43. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Pauly BM, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. *Am J Med* 2005; 118: 1416.

**Supplementary Files**

Please find supplementary file(s): http://dx.doi.org/10.1253/circrep.CR-19-0052